Morgan Stanley analyst Simeon Gutman maintains Five Below (NASDAQ:FIVE) with a Overweight and lowers the price target from $150 to $140.
Merck’s Two Keytruda Combo Cancer Trials Miss Primary Goal
Merck & Co Inc’s (NYSE:MRK) Phase 3 KEYNOTE-921 trial of Keytruda combined with chemotherapy (docetaxel) did not meet its dual…